This study focuses on people who have advanced non-small cell lung cancer (NSCLC) and who had previous treatment using chemotherapy that contains platinum and immunotherapy. The study is part of Lung-MAP, a large research project about lung cancer consisting of various clinical trials that test new treatments for NSCLC. Each clinical trial in Lung-MAP is called a sub-study. In this sub-study, participants will be randomly assigned to receive either the usual treatment (ramucirumab and docetaxel) or the usual treatment plus the study drug, cemiplimab. The addition of cemiplimab to the usual treatment could shrink the cancer but may also cause side effects. Researchers hope to learn whether adding the study drug to usual treatment can help patients live longer. The usual treatment drugs, docetaxel and ramucirumab, are approved by the U.S. Food and Drug Administration (FDA) for use in treating lung cancer, but its combined use with cemiplimab in this study is considered experimental.
What is the full name of this clinical trial?
S1800E: A Randomized Phase II/III Study of Docetaxel and Ramucirumab with or without Cemiplimab for Participants Previously Treated with Platinum-based Chemotherapy and Immunotherapy for Stage IV or Recurrent Non-Small Cell Lung Cancer